Mitochondrial pathology in inclusion body myositis

Neuromuscular Disorders

Volumn 25, Issue 4, 2015, Pages 281-288

  Lindgren, Ulrika ^a   Roos, Sara ^a   Hedberg Oldfors, Carola ^a   Moslemi, Ali Reza ^a   Lindberg, Christopher ^b   Oldfors, Anders ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytochrome c oxidase deficiency; Inclusion body myositis; Mitochondrial DNA; MtDNA

Indexed keywords

CYTOCHROME C OXIDASE; MITOCHONDRIAL DNA; C10ORF2 PROTEIN, HUMAN; DNA DIRECTED DNA POLYMERASE; DNA HELICASE; MITOCHONDRIAL PROTEIN; POLG PROTEIN, HUMAN;

ARTICLE; C10ORF2 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA2 GENE; ENZYME DEFICIENCY; GENE; GENE DELETION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; MGME1 GENE; MORPHOMETRICS; MUSCLE CELL; NEXT GENERATION SEQUENCING; OPA1 GENE; POLG GENE; POLG2 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RRM2B GENE; SANGER SEQUENCING; SLC25A4 GENE; TYMP GENE; AGED; CELL SIZE; CYTOCHROME C OXIDASE DEFICIENCY; FEMALE; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; SKELETAL MUSCLE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL SIZE; CYTOCHROME-C OXIDASE DEFICIENCY; DNA HELICASES; DNA, MITOCHONDRIAL; DNA-DIRECTED DNA POLYMERASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; MUSCLE FIBERS, SKELETAL; MYOSITIS, INCLUSION BODY; SEQUENCE DELETION;

EID: 84925257634     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.12.010     Document Type: Article

References (41)

1. Needham M., Mastaglia F.L. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007, 6:620-631.
2. Badrising U.A., Maat-Schieman M.L., van Houwelingen J.C., et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol 2005, 252:1448-1454.
3. Cox F.M., Titulaer M.J., Sont J.K., Wintzen A.R., Verschuuren J.J., Badrising U.A. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011, 134:3167-3175.
4. Benveniste O., Guiguet M., Freebody J., et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011, 134:3176-3184.
5. Needham M., Corbett A., Day T., Christiansen F., Fabian V., Mastaglia F.L. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008, 15:1350-1353.
6. Greenberg S.A. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol 2012, 25:630-639.
7. Oldfors A., Lindberg C. Diagnosis, pathogenesis and treatment of inclusion body myositis. Curr Opin Neurol 2005, 18:497-503.
8. Oldfors A., Moslemi A.R., Jonasson L., Ohlsson M., Kollberg G., Lindberg C. Mitochondrial abnormalities in inclusion-body myositis. Neurology 2006, 66:S49-S55.
9. Oldfors A., Larsson N.G., Lindberg C., Holme E. Mitochondrial DNA deletions in inclusion body myositis. Brain 1993, 116(Pt 2):325-336.
10. Rygiel K.A., Miller J., Grady J.P., Rocha M.C., Taylor R.W., Turnbull D.M. Mitochondrial and inflammatory changes in sporadic inclusion body myositis. Neuropathol Appl Neurobiol 2014, 10.1111/nan.12149.
11. Dahlbom K., Lindberg C., Oldfors A. Inclusion body myositis: morphological clues to correct diagnosis. Neuromuscul Disord 2002, 12:853-857.
12. Brady S., Squier W., Sewry C., Hanna M., Hilton-Jones D., Holton J.L. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open 2014, 4. e004552.
13. Oldfors A., Moslemi A.R., Fyhr I.M., Holme E., Larsson N.G., Lindberg C. Mitochondrial DNA deletions in muscle fibers in inclusion body myositis. J Neuropathol Exp Neurol 1995, 54:581-587.
14. Trifunovic A., Wredenberg A., Falkenberg M., et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429:417-423.
15. Moslemi A.R., Lindberg C., Oldfors A. Analysis of multiple mitochondrial DNA deletions in inclusion body myositis. Hum Mutat 1997, 10:381-386.
16. Anvret A., Westerlund M., Sydow O., et al. Variations of the CAG trinucleotide repeat in DNA polymerase gamma (POLG1) is associated with Parkinson's disease in Sweden. Neurosci Lett 2010, 485:117-120.
17. Balafkan N., Tzoulis C., Muller B., et al. Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. Mitochondrion 2012, 12:640-643.
18. Eerola J., Luoma P.T., Peuralinna T., et al. POLG1 polyglutamine tract variants associated with Parkinson's disease. Neurosci Lett 2010, 477:1-5.
19. Ronchi D., Di Fonzo A., Lin W., et al. Mutations in DNA2 link progressive myopathy to mitochondrial DNA instability. Am J Hum Genet 2013, 92:293-300.
20. Kornblum C., Nicholls T.J., Haack T.B., et al. Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease. Nat Genet 2013, 45:214-219.
21. Hudson G., Amati-Bonneau P., Blakely E.L., et al. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 2008, 131:329-337.
22. Suomalainen A., Isohanni P. Mitochondrial DNA depletion syndromes-many genes, common mechanisms. Neuromuscul Disord 2010, 20:429-437.
23. Sharer J.D. The adenine nucleotide translocase type 1 (ANT1): a new factor in mitochondrial disease. IUBMB Life 2005, 57:607-614.
24. Dubowitz V., Sewry C.A., Oldfors A. Muscle biopsy - a practical approach 2013, Saunders Elsevier. fourth ed.
25. Kollberg G., Moslemi A.R., Darin N., et al. POLG1 mutations associated with progressive encephalopathy in childhood. J Neuropathol Exp Neurol 2006, 65:758-768.
26. Exome Variant Server NHLBI GO Exome Sequencing Project (ESP), Seattle WA [database on the Internet], v.0.0.28, accessed 01.08.14. http://evs.gs.washington.edu/EVS/.
27. Moslemi A.R., Melberg A., Holme E., Oldfors A. Autosomal dominant progressive external ophthalmoplegia: distribution of multiple mitochondrial DNA deletions. Neurology 1999, 53:79-84.
28. Roos S., Macao B., Fuste J.M., et al. Subnormal levels of POLgammaA cause inefficient initiation of light-strand DNA synthesis and lead to mitochondrial DNA deletions and progressive external ophthalmoplegia [corrected]. Hum Mol Genet 2013, 22:2411-2422.
29. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760.
30. PolyPhen-2 [database on the Internet], v.2.2.2, accessed 04.08.14. http://genetics.bwh.harvard.edu/pph2/.
31. Adzhubei I.A., Schmidt S., Peshkin L., et al. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249.
32. Ng P.C., Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001, 11:863-874.
33. SIFT [database on the Internet], v. 5.2.0, accessed 04.08.14. http://sift.bii.a-star.edu.sg.
34. Kent W.J.S.C., Furey T.S., Roskin K.M., Pringle T.H., Zahler A.M., Haussler D. The human genome browser at UCSC. Genome Res 2002, 12:996-1006.
35. Tang S., Wang J., Lee N.C., et al. Mitochondrial DNA polymerase gamma mutations: an ever expanding molecular and clinical spectrum. J Med Genet 2011, 48:669-681.
36. Sarzi E., Bourdon A., Chretien D., et al. Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood. J Pediatr 2007, 150:531-534.
37. Human DNA Polymerase gamma mutation database [database on the Internet], accessed 16.06.14. http://tools.niehs.nih.gov/polg/.
38. Naimi M., Bannwarth S., Procaccio V., et al. Molecular analysis of ANT1, TWINKLE and POLG in patients with multiple deletions or depletion of mitochondrial DNA by a dHPLC-based assay. Eur J Hum Genet 2006, 14:917-922.
39. Bender A., Krishnan K.J., Morris C.M., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006, 38:515-517.
40. Duan J., Wainwright M.S., Comeron J.M., et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003, 12:205-216.
41. Sauna Z.E., Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 2011, 12:683-691.